Justin Zelen's questions to MEI Pharma (MEIP) leadership • Q4 2021
Question
Justin Zelen of BTIG asked about the broader development plan and the expected cadence of data releases for expanding zandelisib into other indications following the initial monotherapy data in follicular lymphoma.
Answer
Dan Gold, President and CEO, outlined a strategy focused on establishing zandelisib as a backbone therapy through various combinations. He highlighted ongoing and planned studies combining zandelisib with zanubrutinib, rituximab, and venetoclax across follicular lymphoma, mantle cell lymphoma, and CLL. The goal is to provide effective, non-chemotherapy combination regimens in earlier lines of therapy and additional indications.